Patient-Derived Xenograft (PDX) Models

More clinically relevant: models derived from patients that truly mimic human disease

invivo-magnifyglass.png

The World’s Largest Collection of Well-Characterized Patient-Derived Xenograft Models

Patient-derived xenograft (PDX) models offer the most translational research tool for preclinical efficacy screening in cancer drug development. With major challenges facing treatment progression through the clinical setting, PDX models’ heterogeneity and their reflection of the human patient population, allow researchers to better understand how a treatment will perform prior to entering the clinic.

The CrownBio PDX collection:

  • Over 2,500 models representing more than 30 cancer types to test novel therapeutic uses for existing molecules

  • Extensive characterization data found in our searchable PDX database, HuBase™, including: RNAseq, whole exome sequencing, histology, growth kinetics, and SoC treatment data

  • Large collections of 100+ PDX models for colorectal cancer, lung cancer, melanoma, sarcoma, pancreatic cancer, and gastric cancer

  • Exclusive ALL and AML blood cancer PDX models

  • Unique models of specific disease pathways for targeted therapy such as RET, ALK, EGFR, MET, IDH, RSPO, and HER2
 ALL
 AML
Adrenal
Bladder
Brain
Breast
Cervical
Cholangiocarcinoma
Colorectal
Esophageal
Fallopian
Gallbladder
Gastric
GIST
Head and neck
Kidney
Liver
Lung
Lymphoma
Melanoma
Mesothelioma
Mixed mullerian
Ovarian
Pancreatic
Peritoneal
Sarcoma
Testis
Thyroid
Uterine